Project Grant R21AI202338
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $251K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded the Regents of the University of Colorado, doing business as University of Colorado-Denver, $186,953 on February 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify and characterize a secreted protease from Corynebacterium that inhibits Staphylococcus aureus virulence. The project grant (R21AI196550) runs through January 31, 2028, with work performed in Aurora, Colorado. The...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the Regents of the University of Colorado-Denver a $2,637,034 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 8, 2025, with completion targeted for July 31, 2029. This award funds biomedical research investigating the molecular mechanisms by which the actin-binding protein synaptopodin facilitates intracellular bacterial spread,...
- The National Institute of Allergy and Infectious Diseases awarded $766,730 to the University of Colorado-Denver on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate bacteriocins produced by Staphylococcus hominis skin commensals and their protective mechanisms against skin pathogens. The research focuses on identifying and characterizing diverse bacteriocins produced by S. hominis strains isolated from human skin that inhibit pathogenic S....
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $806,000 on May 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of secreted bacterial effectors in Group B Streptococcus (GBS) intestinal colonization and systemic neonatal infection. The research examines how GBS type VII secretion system effectors promote intestinal dysbiosis, impair immune responses, disrupt intestinal barrier function, and...
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of Colorado, doing business as University of Colorado-Denver, $739,968 on June 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research into Staphylococcus aureus metabolic requirements during skin colonization. The project investigates how S. aureus, which causes 76 percent of all skin infections and asymptomatically colonizes the skin of 8–22 percent of healthy...
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of Colorado, doing business as University of Colorado-Denver, $771,983 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate gastrointestinal tissue-adapted eosinophils in health and disease. The project, titled "Gastrointestinal Tissue-Adapted Eosinophils in Health and Disease," uses targeted high-dimensional flow cytometry,...
- The National Institute of Allergy and Infectious Diseases awarded The Regents Of The University Of Colorado (doing business as University Of Colorado-Denver) $153,680 on November 1, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research investigates the role of type 1 interferon signaling in promoting antigen archiving and vaccine stability within lymphatic endothelial cells. Lymphatic endothelial cells serve as the first point of contact for antigens and...
- The National Institute of Allergy and Infectious Diseases awarded The Regents Of The University Of Colorado, doing business as University Of Colorado-Denver, $412,422 on February 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate IGA regulation of Candida glabrata within the intestinal microbiome. The recipient will identify IGA-targeted C. glabrata effectors and examine their role in adhering to the intestinal epithelium and inducing invasive...
- The National Institute of Allergy and Infectious Diseases (a component of the Department of Health and Human Services National Institutes of Health) awarded $713,873 to The Regents of The University of Colorado (University of Colorado-Denver) on May 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, assistance type Project Grant R01AI198189). The award funds research to define mechanistically how discrete lymph node stromal cells regulate viral dissemination to...
- The National Institute of Allergy and Infectious Diseases awarded Colorado State University $423,500 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate bacteriophage interactions with nontuberculous mycobacteria in mammalian cell intracellular environments. The research addresses the therapeutic use of bacteriophages—naturally occurring viruses that infect and kill bacteria—as an alternative treatment for drug-resistant nontuberculous...